Kidney cancer drug combo trial halted early – what we know
NCT ID NCT03260504
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial tested a combination of two immunotherapy drugs, aldesleukin (IL-2) and pembrolizumab, in 6 people with advanced kidney cancer that had spread. The goal was to find the safest dose and see if the combination could shrink tumors. The study was terminated early, so results are limited, but it aimed to boost the immune system to fight the cancer more effectively.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fred Hutch/University of Washington Cancer Consortium
Seattle, Washington, 98109, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a tracer that hunts unstable iron light up hidden tumors?
- New imaging agent aims to spot Hard-to-Find kidney cancer spread
- New PET scan could reveal kidney cancer drug success in weeks, not months
- Cell therapy combo aims to boost kidney cancer treatment
- New drug duo aims to shrink advanced kidney tumors
- New scan could reveal hidden kidney cancer